Market Research Report
Asia Pacific Active Pharmaceutical Ingredients Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||819213|
|Published||Content info||90 Pages
Delivery time: 2-3 business days
|Asia Pacific Active Pharmaceutical Ingredients Market Forecast 2019-2027|
|Published: April 8, 2019||Content info: 90 Pages||
There are various chemicals included in the drugs and the portion that works in treating the condition, i.e., the active part is known as 'Active Pharmaceutical Ingredients' or API in short. While each drug also consists of an excipient part, known as a carrier, it is the API that is considered while prescribing a drug.
The Asia Pacific active pharmaceutical ingredients market is escalating at a significant growth rate of 7.45% CAGR during the forecasting years of 2019-2027. The availability of cheap labor in this densely populated region coupled with the establishment of market players in the developing countries in APAC is expected to drive the market growth.
The economies of China, India, Japan, South Korea, Australia and the remaining countries collectively forming the Rest of Asia Pacific regional segment are the major revenue contributors to the APAC active pharmaceutical ingredients market. The healthcare expenditure in China is projected to reach a huge value soon because the nation shelters the largest population in the world, where there has been a significant rise in chronic conditions such as that of cancer, cardiovascular diseases, diabetes, and obesity, etc. These factors collectively create a huge scope for API market development.
Japan makes up another significantly large market in the Asia Pacific region for the API market. The high rise in geriatric population in the country coupled with higher expectation for an enhanced quality of life will be driving the market demand in the country.
The major market players operating in the APAC region, which are exhaustively profiled in terms of their adopted market strategies, business segments are Teva Pharmaceutical Industries, Ltd., Merck & Co., Inc., Abbvie, Inc., Cipla, Bristol-Myers Squibb, Dr. Reddy's Laboratories, Sun Pharmaceuticals Industries, Ltd., Mylan N.V., Bayer AG, Eli Lilly and Company, Novartis, Albemarle Corporation, Lonza Group AG, Aurobindo Pharma, and Boehringer Ingelheim GmbH.